Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease

JAMA

Volumn 281, Issue 18, 1999, Pages 1722-1727

  Smith, J Kelly ^a   Dykes, Rhesa ^a   Douglas, John E ^a   Krishnaswamy, Guha ^a   Berk, Steven ^a  

^a East Tennessee State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; MONONUCLEAR CELL; OBESITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; SMOKING; TREADMILL EXERCISE;

EID: 0033549059     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.18.1722     Document Type: Article

References (53)

1. Centers for Disease Control and Prevention. Mortality patterns: preliminary data, United States, 1996. MMWR Morb Mortal Wkly Rep. 1997;46:941-944.
2. Paffenbarger RS Jr, Wing AL, Hyder T. Physical activity as an index of heart attack risk in college alumni. Am J Epidemiol. 1978;108:161-175.
3. Blair SN, Kohl HW III, Paffenbarger RS Jr, Clark DG, Cooper KG, Gibbons LW. Physical fitness and all-cause mortality: a prospective study of healthy men and women. JAMA. 1989;262:2395-2401.
4. Lee IM, Hsieh CC, Paffenbarger RS Jr. Exercise intensity and longevity in men: the Harvard Alumni Study. JAMA. 1995;273:1179-1184.
5. Blair SN, Kohl HW III, Barlow CE, Paffenbarger RS Jr, Gibbons LW, Macera CA. Changes in physical fitness and all-cause mortality. JAMA. 1995;273:1093-1098.
6. Blair SN, Kampert JB, Kohl HW III, et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA. 1996;276:205-210.
7. Kushi LH, Fee RM, Folsom AR, Mink PJ, Anderson KE, Sellers TA. Physical activity and mortality in postmenopausal women. JAMA. 1997;277:1287-1292.
8. Kujala UM, Kaprio J, Sarna S, Koskenvuo M. Relationship of leisure-time physical activity and mortality: the Finnish twin cohort. JAMA. 1998;279:440-444.
9. Hakim AA, Petrovitch H, Burchfiel CM, et al. Effects of walking on mortality among nonsmoking retired men. N Engl J Med. 1998;338:93-94.
10. National Institutes of Health Consensus Development Panel on Physical Activity and Cardiovascular Health. Physical activity and cardiovascular health. JAMA. 1996;276:241-246.
11. American College of Sports Medicine. Physical activity, physical fitness, and hypertension: position stand. Med Sci Sports Exerc. 1993;25:1-10.
12. Blair SN. Evidence for success of exercise in weight loss and control. Ann Intern Med. 1993;119:702-706.
13. Stefanick ML, Wood PD. Physical activity, lipid and lipoprotein metabolism, and lipid transport. In: Bouchard C, Shephard RJ, Stephens T, eds. Physical Activity, Fitness, and Health: International Proceedings and Consensus Statement. Champaign, III: Human Kinetics Publishers Inc; 1994:417-431.
14. Mayer-Davis EJ, D'Agostino R Jr, Kerter AJ, et al. Intensity and amount of physical activity in relation to insulin sensitivity: the insulin resistance atherosclerosis study. JAMA. 1998;339:669-674.
15. Van Der Wal AC, Das Pk, Van De Berg DB, Van Der Loos CM, Becker AE. Atherosclerotic lesions in humans: in situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest. 1989;61:166-170.
16. Munro JM, Cotran RS. Biology of disease: the pathogenesis of atherosclerosis, atherogenesis and inflammation. Lab Invesf. 1988;58:249-261.
17. Libby P, Hansson GK. Biology of disease involvements of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-15.
18. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
19. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;16:27-33.
20. Yokota T, Hansson GK. Immunological mechanisms in atherosclerosis. J Intern Med. 1995;238:479-489.
21. Watanabe T, Haraoka S, Shimokama T. Inflammatory and immunological nature of atherosclerosis. Int J Cardiol. 1996;54(suppl):S51-S60.
22. Selwyn AP, Kinlay S, Ganz P. Atherogenesis and ischemic heart disease. Am J Cardiol. 1997;80:3H-7H.
23. Wick G, Romen M, Amberger A, et al. Atherosclerosis, autoimmunity, and vascular-associated lymphoid tissue. FASEB J. 1997;11:1199-1207.
24. Campbell JH, Campbell GR. The cell biology of atherosclerosis: new developments. Aust N Z J Med. 1997;27:497-500.
25. Adam E, Melnick JL, Probtsfield JL, et al. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet. 1987;2:291-293.
26. Yamashiroya HM, Ghosh L, Yang R, Robertson AL Jr. Herpesviridae in the coronary arteries and aorta of young trauma victims. Am J Pathol. 1988;130:71-79.
27. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci U S A. 1995;92:6911-6914.
28. Witztum JL. Immunological responses to oxidized LDL. Atherosclerosis. 1997;131:S9-S11.
29. Labarrere CA, Nelson DR, Faulk WP. Endothelial activation and development of coronary artery disease in transplanted human hearts. JAMA. 1997;278:1169-1175.
30. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
31. Danesh J, Collins R, Appleby P, Petro R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary artery disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-1482.
32. Muscari A, Bozzoli C, Puddu GM, et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med. 1995;98:357-364.
33. Borish L, Rosenwasser LJ. Update on cytokines. J Allergy Clin Immunol. 1996;97:719-733.
34. Te Velde AA, Huijbens RJF, Heije K, de Vries JE, Fidgor CG. Interleukin-4 (IL-4) inhibits secretion of IL-1α, tumor necrosis factor α, and IL-6 by human monocytes. Blood. 1990;76:1392-1397.
35. Elliot MJ, Gamble JR, Park LS, Vadas MA, Lopez AE. Inhibition of human monocyte adhesion by interleukin-4. Blood. 1991;12:2739-2745.
36. Fenton MJ, Buras JA, Donnelly RP. IL-4 reciprocally regulates IL-1 and IL-1 receptor antagonist expression in human monocytes. J Immunol. 1992;149:1283-1288.
37. Vasse M, Paysant J, Soria J, Mirshahi S, Vannier JP, Soria C. Down-regulation of fibrinogen biosynthesis by IL-4, IL-10 and IL-13. Br J Haematol 1996;93:955-961.
38. Krakauer T. IL-10 inhibits the adhesion of leukocyte cells to IL-1 activated human endothelial cells. Immunol Lett. 1995;45:61-65.
39. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991;147:3815-3822.
40. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med. 1991;174: 1549-1555.
41. Grazinelli TT, Oswald IP, James SL, Sher A. IL-10 inhibits parasite killing and nitrogen production by IFNγ-activated macrophages, J Immunol. 1992;148: 1792-1799.
42. D'Andrea A, Aste-Amezaga M, Vaiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon-γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med. 1993;178:1041-1048.
43. Uyemura K, Demer LL, Castle SC, et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest. 1996;97:2130-2138.
44. Vadas MA, Gamble JR, Rye K, Barter P. Regulation of leucocyte-endothelial interactions of special relevance to atherogenesis. Clin Exp Pharmacol Physiol. 1997;24:A33-A35.
45. Grainger DJ, Byrne CD, Witchell CM, Metcalfe JC. Transforming growth factor beta is sequestered into an inactive pool by lipoproteins. J Lipid Res. 1997; 38:2344-2352.
46. Tashiro H, Shimokawa H, Yamamoto K, Momohara M, Tada H, Takeshita A, Altered plasma levels of cytokines in patients with ischemic heart disease. Coran Artery Dis. 1997;8:143-147.
47. Reckless J, Metcalfe JC, Granger DJ. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation. 1997;95:1542-1548.
48. Angles-Cano E. Structural basis for the pathophysiology of lipoprotein (a) in the athero-thrombotic process. Braz J Med Biol Res. 1997;30:1271-1280.
49. Di Febbo C, Baccante G, Reale M, et al. Transforming growth factor beta induces IL-1 receptor antagonist production and gene expression in rat vascular smooth muscle cells. Atherosclerosis. 1998;136:377-382.
50. Takami S, Yamashita S, Kihara S, et al. Lipoprotein (a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation. 1998;97:721-728.
51. Maluish AE, Strong DM. Lymphocyte proliferation. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Immunology. Washington, DC: American Society for Microbiology; 1986:274-281.
52. Farrar MA, Schreiber RD. The molecular cell biology of Interferon-γ and its receptor. Annu Rev Immunol. 1993;11:571-611.
53. Gupta S, Pablo AM, Jiang XC, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997;99:2752-2761.